EP2403447A4 - Agents bioactifs microencapsulés pour administration orale et méthodes d'utilisation associées - Google Patents

Agents bioactifs microencapsulés pour administration orale et méthodes d'utilisation associées

Info

Publication number
EP2403447A4
EP2403447A4 EP10749385.0A EP10749385A EP2403447A4 EP 2403447 A4 EP2403447 A4 EP 2403447A4 EP 10749385 A EP10749385 A EP 10749385A EP 2403447 A4 EP2403447 A4 EP 2403447A4
Authority
EP
European Patent Office
Prior art keywords
methods
oral administration
bioactive agents
microencapsulated bioactive
microencapsulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP10749385.0A
Other languages
German (de)
English (en)
Other versions
EP2403447B1 (fr
EP2403447A1 (fr
Inventor
Daniel R Debrouse
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TAMARISK TECHNOLOGIES GROUP LLC
Original Assignee
DelivRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DelivRx Inc filed Critical DelivRx Inc
Publication of EP2403447A1 publication Critical patent/EP2403447A1/fr
Publication of EP2403447A4 publication Critical patent/EP2403447A4/fr
Application granted granted Critical
Publication of EP2403447B1 publication Critical patent/EP2403447B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/035—Halogenated hydrocarbons having aliphatic unsaturation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10749385.0A 2009-03-06 2010-03-05 Agents bioactifs microencapsulés pour administration orale et méthodes d'utilisation associées Active EP2403447B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15823109P 2009-03-06 2009-03-06
PCT/US2010/026351 WO2010102198A1 (fr) 2009-03-06 2010-03-05 Agents bioactifs microencapsulés pour administration orale et méthodes d'utilisation associées

Publications (3)

Publication Number Publication Date
EP2403447A1 EP2403447A1 (fr) 2012-01-11
EP2403447A4 true EP2403447A4 (fr) 2014-02-19
EP2403447B1 EP2403447B1 (fr) 2019-10-16

Family

ID=42710022

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10749385.0A Active EP2403447B1 (fr) 2009-03-06 2010-03-05 Agents bioactifs microencapsulés pour administration orale et méthodes d'utilisation associées

Country Status (6)

Country Link
US (2) US20100226995A1 (fr)
EP (1) EP2403447B1 (fr)
AU (1) AU2010221209C1 (fr)
CA (1) CA2757767C (fr)
WO (1) WO2010102198A1 (fr)
ZA (1) ZA201107285B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA201107285B (en) * 2009-03-06 2012-12-27 Delivtx Inc Microencapsulated bioactive agents for oral delivery and methods of the thereof
US9504736B2 (en) 2010-09-23 2016-11-29 The Regents Of The University Of California Administration of serine protease inhibitors to the stomach
EP2640361B1 (fr) * 2010-11-16 2019-09-11 Provimi North America Inc. Additif pour aliments du bétail à base de métabisulfite de sodium à enrobage gastrorésistant utilisé pour la détoxication de la vomitoxine
US8349799B1 (en) 2012-01-07 2013-01-08 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US10125335B2 (en) * 2013-06-28 2018-11-13 Castrol Limited Lubricating compositions containing isoprene based components
MX2016004012A (es) 2013-10-02 2016-10-26 Can Tech Inc Granulos de pienso y sistemas y metodos relacionados.
CN112807325A (zh) 2014-03-25 2021-05-18 恒翼生物医药科技(上海)有限公司 用于治疗自身消化的组合物
MX383492B (es) 2014-07-01 2025-03-04 Probi Usa Inc Comprimidos probióticos bicapa de doble liberación.
DK3294073T3 (da) * 2015-05-11 2022-11-14 Mybiotics Pharma Ltd Systemer og fremgangsmåder til dyrkning af en biofilm af probiotiske bakterier på faste partikler til kolonisering af bakterier i tarmen
CN106609064A (zh) * 2015-10-22 2017-05-03 李继成 洗车用吸附颗粒成膜液
CA3010986A1 (fr) 2016-01-11 2017-07-20 Leading BioSciences, Inc. Compositions et methodes pour traiter et prevenir les adherences et l'ileus
US20190175507A1 (en) * 2016-06-03 2019-06-13 Tamarisk Technologies Group Llc Compositions for oral administration of active agents
JP2019518797A (ja) * 2016-06-27 2019-07-04 タマリスク、テクノロジーズ、グループ、リミテッド、ライアビリティ、カンパニーＴａｍａｒｉｓｋ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｇｒｏｕｐ Ｌｌｃ ペプチドおよびタンパク質の送達のための医薬製剤
WO2018004906A1 (fr) * 2016-07-01 2018-01-04 Wake Forest University Hydrogels d'alginate modifiés pour agents thérapeutiques, leur préparation et procédés associés
US10766970B2 (en) 2016-07-01 2020-09-08 Wake Forest University Health Sciences Modified carbohydrates, compositions comprising the same, and methods of making and using the same
JP7045467B2 (ja) * 2018-08-30 2022-03-31 富士フイルム株式会社 外用ゲル組成物およびその使用方法
US12350367B2 (en) * 2019-09-12 2025-07-08 Nulixir Inc. Particles for administration of active ingredients and methods of making the same
KR20220090617A (ko) * 2020-12-22 2022-06-30 (주)메디언스 우유 단백질의 분획물을 주요 성분으로 포함하는 구강 내 흡수 촉진용 조성물
US12409187B2 (en) 2021-03-31 2025-09-09 Brown University PH regulating hydrogels that neutralize cancer cell environment acidosis and increase chemotherapy efficacy
CN112931907B (zh) * 2021-04-06 2023-01-31 大连工业大学 一种基于分离乳清蛋白提高虾青素释放率的微球制备方法
CN118717644A (zh) * 2024-06-14 2024-10-01 苏州大学 一种3d打印的肠道递送载体及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018186A1 (fr) * 2001-08-23 2003-03-06 Bio-Dar Ltd. Microcapsules enrobees stables
US20060088592A1 (en) * 2004-04-28 2006-04-27 Seung-Ho Choi Oral formulation for delivery of poorly absorbed drugs
WO2007083984A1 (fr) * 2006-01-23 2007-07-26 Gwangju Institute Of Science And Technology Conjugué comprenant un composé pharmaceutiquement actif lié de façon covalente à un polymère mucoadhésif et méthode d'administration transmucosale de composé pharmaceutiquement actif faisant appel audit conjugué

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126672A (en) * 1976-02-04 1978-11-21 Hoffmann-La Roche Inc. Sustained release pharmaceutical capsules
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
ES2270426T3 (es) * 1994-03-18 2007-04-01 Supernus Pharmaceuticals, Inc. Sistema de suministros de farmacos emulsionados.
EP0833617A1 (fr) * 1995-06-20 1998-04-08 Pharma-Vinci A/S Procede de confection d'une preparation orale presentant exterieurement un enrobage de delitage enterique et preparation orale obtenue selon le procede
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
FR2757173A1 (fr) * 1996-12-17 1998-06-19 Warner Lambert Co Compositions polymeres d'origine non-animale pour la formation de films
US6093692A (en) * 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6365185B1 (en) * 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
US20030124196A1 (en) * 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US8383158B2 (en) * 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
WO2007143507A2 (fr) * 2006-06-05 2007-12-13 Auspex Pharmaceuticals, Inc. Préparation et utilité d'analogues d'érythromycine substitués
ZA201107285B (en) * 2009-03-06 2012-12-27 Delivtx Inc Microencapsulated bioactive agents for oral delivery and methods of the thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018186A1 (fr) * 2001-08-23 2003-03-06 Bio-Dar Ltd. Microcapsules enrobees stables
US20060088592A1 (en) * 2004-04-28 2006-04-27 Seung-Ho Choi Oral formulation for delivery of poorly absorbed drugs
WO2007083984A1 (fr) * 2006-01-23 2007-07-26 Gwangju Institute Of Science And Technology Conjugué comprenant un composé pharmaceutiquement actif lié de façon covalente à un polymère mucoadhésif et méthode d'administration transmucosale de composé pharmaceutiquement actif faisant appel audit conjugué

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2010102198A1 *

Also Published As

Publication number Publication date
EP2403447B1 (fr) 2019-10-16
ZA201107285B (en) 2012-12-27
US20140037743A1 (en) 2014-02-06
AU2010221209A1 (en) 2011-11-03
AU2010221209B2 (en) 2015-04-30
US20100226995A1 (en) 2010-09-09
CA2757767C (fr) 2018-01-02
EP2403447A1 (fr) 2012-01-11
US9278077B2 (en) 2016-03-08
CA2757767A1 (fr) 2010-09-10
WO2010102198A1 (fr) 2010-09-10
AU2010221209C1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
EP2403447A4 (fr) Agents bioactifs microencapsulés pour administration orale et méthodes d'utilisation associées
ME03631B (fr) Compositions pour administration respiratoire d'agents actifs et méthodes et systèmes associés
EP2477634A4 (fr) Formulations pour injection d'un antihistaminique non sédatif et leurs méthodes d'utilisation
EP2588130A4 (fr) Administration au snc d'agents thérapeutiques
EP1973986A4 (fr) Compositions bioactives complexes et leurs méthodes d'utilisation
EP2427212A4 (fr) Anticorps anti-cd100 et leurs méthodes d'utilisation
HRP20190100T1 (hr) Oralne formulacije analoga citidina i postupci za njihovu upotrebu
EP2596112A4 (fr) Compositions d'acétylcystéine et méthodes d'utilisation correspondantes
EP2384120A4 (fr) Compositions adjuvantes et méthodes d'utilisation
EP2271353A4 (fr) Procédures d'oxygénation pour nouveau-nés et leurs dispositifs d'utilisation
EP2603201A4 (fr) Compositions liposomiques et leurs méthodes d'utilisation
EP2217696A4 (fr) Nouvelle bactérie et méthodes d'utilisation
EP2482761A4 (fr) Compositions de greffe tissulaire et méthodes d'utilisation
EP2552439A4 (fr) Méthodes d'amélioration de l'administration de médicament et de l'efficacité d'agents thérapeutiques
EP2405942A4 (fr) Produit pour administration orale
IL197833A0 (en) Device for local and/or regional delivery employing liquid formulations of therapeutic agents
EP2265126A4 (fr) Méthodes et compositions pour l administration contrôlée d agents phytochimiques
EP2448406A4 (fr) Compositions pharmaceutiques orales à libération prolongée de 3-hydroxy-n-méthylmorphinane et procédé d'utilisation
EP2597945A4 (fr) Animaux transgéniques et méthodes d'utilisation
EP2649923A4 (fr) Endoscope et dispositif d'éclairement pour endoscope
EP2049054A4 (fr) Interface patient nasale et orale
EP2850188A4 (fr) Compositions et méthodes pour moduler l'expression de la famille multigénique de l'hémoglobine
EP2171096A4 (fr) Polymorphismes de carboxylestérase-1 etleurs méthodes d'utilisation
EP2804601A4 (fr) Compositions contenant des esters de phorbol et méthodes d'utilisation de ces derniers
EP2747832A4 (fr) Formulations d'agents actifs pour une libération prolongée

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111006

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140120

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/44 20060101ALI20140114BHEP

Ipc: A61K 47/26 20060101ALI20140114BHEP

Ipc: A61K 47/02 20060101ALI20140114BHEP

Ipc: A61F 13/00 20060101AFI20140114BHEP

Ipc: A61K 47/36 20060101ALI20140114BHEP

Ipc: A61K 47/10 20060101ALI20140114BHEP

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TAMARISK TECHNOLOGIES GROUP, LLC

17Q First examination report despatched

Effective date: 20150305

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602010061537

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61F0013000000

Ipc: A61K0009500000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/36 20060101ALI20180514BHEP

Ipc: A61K 31/122 20060101ALI20180514BHEP

Ipc: A61K 31/375 20060101ALI20180514BHEP

Ipc: A61K 9/50 20060101AFI20180514BHEP

Ipc: A61K 31/05 20060101ALI20180514BHEP

Ipc: A61K 38/28 20060101ALI20180514BHEP

Ipc: A61K 47/02 20060101ALI20180514BHEP

Ipc: A61K 35/747 20150101ALI20180514BHEP

Ipc: A61K 31/035 20060101ALI20180514BHEP

Ipc: A61K 35/745 20150101ALI20180514BHEP

Ipc: A61K 31/573 20060101ALI20180514BHEP

Ipc: A61K 47/44 20060101ALI20180514BHEP

Ipc: A61K 45/06 20060101ALI20180514BHEP

Ipc: A61K 47/26 20060101ALI20180514BHEP

Ipc: A61K 47/10 20060101ALI20180514BHEP

INTG Intention to grant announced

Effective date: 20180613

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010061537

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 1190615

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191115

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20191016

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1190615

Country of ref document: AT

Kind code of ref document: T

Effective date: 20191016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200217

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200117

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200116

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200116

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200224

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602010061537

Country of ref document: DE

PG2D Information on lapse in contracting state deleted

Ref country code: IS

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200216

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

26N No opposition filed

Effective date: 20200717

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602010061537

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20200331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200305

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201001

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200331

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20200305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200305

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20191016